Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
('Mediclinic', the 'Company', or the 'Group')
25 May 2023
NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM
Vesting of awards under the Company's Short-Term Incentive ('STI') scheme and Long-Term Incentive Plan ('LTIP')
In connection with the recommended cash acquisition of Mediclinic by Manta Bidco Limited (a newly formed company owned by: (i) Remgro Limited and certain of its subsidiaries; and (ii) SAS Shipping Agencies Services S.à r.l., a wholly owned subsidiary of MSC Mediterranean Shipping Company SA) (the 'Acquisition'), this notification sets out the details of the vesting of awards over ordinary shares in Mediclinic granted under the Company's STI and LTIP to Directors and other persons discharging managerial responsibilities ('PDMRs') in the financial years ended on 31 March 2020, 31 March 2021, 31 March 2022 and 31 March 2023.
The awards vested on 24 May 2023 and will be settled in cash, based on the offer price to be paid by Manta Bidco Limited in connection with the Acquisition, being 501 pence per share.
The notifications that follow are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
| 1. | Details of PDMR / person closely associated with them
| |||||||||||||||
| a) | Name | Dr Carel Aron van der Merwe
| ||||||||||||||
| 2. | Reason for the notification
| |||||||||||||||
| a) | Position / status | Group Chief Executive Officer - Mediclinic International plc
| ||||||||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||
| a) | Name | Mediclinic International plc
| ||||||||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||||||||
| 4.1 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 19 June 2019;
2. 14 December 2020;
3. 4 June 2021; and
4. 5 August 2022.
Vesting of deferred awards over ordinary shares in Mediclinic granted at nil cost under the Company's STI on:
5. 4 June 2021; and
6. 5 August 2022
| ||||||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||||||
| d) | Aggregated information
Aggregated volume
Price |
586 861
£nil
| ||||||||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||||||||
| a) | Name | Petrus Jurgens Myburgh
| ||||||||||||||
| 2. | Reason for the notification
| |||||||||||||||
| a) | Position / status | Group Chief Financial Officer - Mediclinic International plc
| ||||||||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||
| a) | Name | Mediclinic International plc
| ||||||||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||||||||
| 4.1 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 19 June 2019;
2. 14 December 2020;
3. 4 June 2021; and
4. 5 August 2022.
Vesting of deferred awards over ordinary shares in Mediclinic granted at nil cost under the Company's STI on:
5. 4 June 2021; and
6. 5 August 2022
| ||||||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||||||
| d) | Aggregated information
Aggregated volume
Price |
345 096
£nil
| ||||||||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Gert Cornelis Hattingh
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Group Chief Governance Officer - Mediclinic International plc
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
68 153
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023
| ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Dr Dirk Cornelius le Roux
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Group Chief Information Officer - Mediclinic International plc
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
53 384
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Dr Daniel Liedtke
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Chief Executive Officer: Hirslanden | ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
120 624
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Magnus Oetiker
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Group Chief Strategy Officer - Mediclinic International plc
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
99 712
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Koert Hendrik Stefanus Pretorius
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Group Chief Operating Officer - Mediclinic International plc
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
71 239
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Dr René Toua
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Group Chief Clinical Officer - Mediclinic International plc
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
55 045
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Dr Tyson Bruno Welzel
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Group Chief Innovation Officer - Mediclinic International plc
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
48 436
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Hein van Eck
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Chief Executive Officer - Mediclinic Middle East
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
4. 14 December 2020;
5. 4 June 2021; and
6. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
15 946
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
| 1. | Details of PDMR / person closely associated with them
| |||||||||
| a) | Name | Greg van Wyk
| ||||||||
| 2. | Reason for the notification
| |||||||||
| a) | Position / status | Chief Executive Officer: Mediclinic Southern Africa
| ||||||||
| b) | Initial notification / amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mediclinic International plc
| ||||||||
| b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||
| b) | Nature of the transaction | Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:
1. 14 December 2020;
2. 4 June 2021; and
3. 5 August 2022.
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information
Aggregated volume
Price |
43 400
£nil
| ||||||||
| e) | Date of the transaction | 24 May 2023 | ||||||||
| f) | Place of the transaction | Outside a trading venue | ||||||||
CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.